Clearmind Medicine Inc. announced a U.S. patent application for a combination therapy targeting binge behavior disorders, in collaboration with SciSparc Ltd. The therapy combines MEAI and PEA to reduce impulsivity and reward-seeking behavior, potentially offering a breakthrough in treating substance use disorders. Clearmind has filed a total of 13 patents related to this collaboration, focusing on conditions such as alcohol use disorder, cocaine addiction, obesity, and depression. The company aims to pioneer safe and effective treatments for binge behaviors, leveraging MEAI’s neuroplastic properties and PEA’s synergistic benefits. Clearmind is listed on Nasdaq under “CMND” and the Frankfurt Stock Exchange under “CWY0.”

Read more at GlobeNewswire: Clearmind Medicine Announces Publication of U.S. Patent